Aristo Bio-Tech and Lifescience (NSE:ARISTO) Debt-to-EBITDA : 3.59 (As of Mar. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Aristo Bio-Tech and Lifescience Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aristo Bio-Tech and Lifescience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was ₹123 Mil. Aristo Bio-Tech and Lifescience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was ₹102 Mil. Aristo Bio-Tech and Lifescience's annualized EBITDA for the quarter that ended in Mar. 2023 was ₹63 Mil. Aristo Bio-Tech and Lifescience's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 was 3.59.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Aristo Bio-Tech and Lifescience's Debt-to-EBITDA or its related term are showing as below:

NSE:ARISTO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.65 Med: 4.92 Max: 5.14
Current: 2.65

During the past 4 years, the highest Debt-to-EBITDA Ratio of Aristo Bio-Tech and Lifescience was 5.14. The lowest was 2.65. And the median was 4.92.

NSE:ARISTO's Debt-to-EBITDA is ranked worse than
55.87% of 179 companies
in the Agriculture industry
Industry Median: 2 vs NSE:ARISTO: 2.65

Aristo Bio-Tech and Lifescience Debt-to-EBITDA Historical Data

The historical data trend for Aristo Bio-Tech and Lifescience's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aristo Bio-Tech and Lifescience Debt-to-EBITDA Chart

Aristo Bio-Tech and Lifescience Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Debt-to-EBITDA

4.86

4.99

5.14

2.65

Aristo Bio-Tech and Lifescience Semi-Annual Data
	Mar20	Mar21	Mar22	Sep22	Mar23
Debt-to-EBITDA	N/A	N/A	N/A	2.74	3.59

Competitive Comparison of Aristo Bio-Tech and Lifescience's Debt-to-EBITDA

For the Agricultural Inputs subindustry, Aristo Bio-Tech and Lifescience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aristo Bio-Tech and Lifescience's Debt-to-EBITDA Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Aristo Bio-Tech and Lifescience's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aristo Bio-Tech and Lifescience's Debt-to-EBITDA falls into.

Aristo Bio-Tech and Lifescience Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Aristo Bio-Tech and Lifescience's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(123.243	+	101.66)	/	84.819
	=	2.65

Aristo Bio-Tech and Lifescience's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(123.243	+	101.66)	/	62.664
	=	3.59

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Mar. 2023) EBITDA data.

Aristo Bio-Tech and Lifescience (NSE:ARISTO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Aristo Bio-Tech and Lifescience Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aristo Bio-Tech and Lifescience's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Aristo Bio-Tech and Lifescience (NSE:ARISTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Aristo Bio-Tech and Lifescience Ltd (NSE:ARISTO) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

E-24, 25, 26, G.I.D.C, Manjusar, Taluka Savli, Vadodara, GJ, IND, 391775

Website

https://www.aristobiotech.com

Aristo Bio-Tech and Lifescience Ltd is an agrochemical company. It is mainly engaged in the manufacturing, formulation, supplying, packaging, and job work services of various pesticides. The company exports products like Insecticides, Herbicides, Fungicides, Plant Growth Regulators, and a wide variety of other Agrochemicals.

Aristo Bio-Tech and Lifescience (NSE:ARISTO) Headlines

No Headlines